US FDA Open To ‘Compromise’ In Regulating Pancreatic Islet Cell Transplantation
Executive Summary
FDA’s Peter Marks says there may be a way to reduce the regulatory burden for pancreatic islet cell treatment for diabetes. Researchers in Canada and Europe note access to therapy is limited in the US since FDA regulates islet cells as a drug while other countries regulate them as a tissue or organ.